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Abstract
Background: Aim of this study is to thoroughly assess pretreatment organ function in advanced
head and neck cancer through various clinical outcome measures and patients' views.
Methods: A comprehensive, multidimensional assessment was used, that included quality of life,
swallowing, mouth opening, and weight changes. Fifty-five patients with stage III-IV disease were
entered in this study prior to organ preserving (chemoradiation) treatment.
Results: All patients showed pretreatment abnormalities or problems, identified by one or more
of the outcome measures. Most frequent problems concerned swallowing, pain, and weight loss.
Interestingly, clinical outcome measures and patients' perception did no always concur. E.g.
videofluoroscopy identified aspiration and laryngeal penetration in 18% of the patients, whereas
only 7 patients (13%) perceived this as problematic; only 2 out of 7 patients with objective trismus
actually perceived trismus.
Conclusion: The assessment identified several problems already pre-treatment, in this patient
population. A thorough assessment of both clinical measures and patients' views appears to be
necessary to gain insight in all (perceived) pre-existing functional and quality of life problems.
Background
In recent years chemoradiation (CRT) has become an
indispensable treatment modality for advanced head and
neck cancer, improving local control and overall survival
in all sites, except in the (stage IV) laryngeal cancers [1-3].
Unfortunately, CRT can have a detrimental effect on organ
function, and on patients' quality of life [4]. But even
before the onset of treatment patients may present with
pain, impaired swallowing, aspiration, dietary restrictions
and even with tube dependency, as well as trismus and
loss of body weight, because the tumor may disrupt the
normal anatomy and thus interfere with normal function
[5-11]. Many studies have indeed investigated typical
problems associated with head and neck cancer [12-16].
However, the majority of earlier research has focused on
posttreatment dysfunction [4]. Moreover, the studies
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investigating problems associated with head and neck
cancer tend to focus on only a limited set of functional
aspects.
A systematic search of the literature, covering the period
between January 1997 to August 2007 [4], shows that two
assessment tools are commonly used in the literature.
Quality of life (QOL) questionnaires are frequently used
to evaluate patients' perceived quality of life -where other
functional outcomes such as pain and nutrition are gener-
ally part of the QOL questionnaire [4] -, or Videofluoro-
scopic Modified Barium Swallow (VMBS) examinations
are used to assess swallowing function [4]. VMBS exami-
nations only assess the structures and dynamics of the
swallowing process, and do not assess the influence of the
swallowing problems on the patients' overall quality of
life (personal perception of well-being). In the literature
only a few studies combine VMBS examinations with
QOL questionnaires [6-8,11]. These studies also show
some limitations; i.e. the VMBS was only performed after
CRT and based on patient or clinician appreciated swal-
lowing difficulties beyond that expected after treatment
[7]; the authors did not use a QOL questionnaire to ana-
lyze the patients' perceived problems, but only one single
question [8] or a 7-point scale [11]; or the authors did not
correlate the VMBS examinations to the QOL outcomes
[6].
As mentioned above, the problems associated with head
and neck cancer may involve many different functional
aspects, most of which deteriorate even further through
CRT. It is therefore imperative that a comprehensive mul-
tidimensional assessment is applied to identify existing
problems before onset of treatment and monitor these
problems during and post-treatment. This not only pro-
vides important baseline measurements to evaluate the
effects of e.g. preventive and/or therapeutic rehabilitation
programs, but also allows thorough analysis and compar-
ison of the subjective patient-perceived and objective cli-
nician-measured treatment outcomes.
The aim of this study is to evaluate the pretreatment organ
function in advanced head and neck cancer patients
through patients' view and clinical measures. The correla-
tions between, and the importance of the different subjec-
tive patient-perceived as well as objective clinician-
measured aspects are reported in this study.
Methods
During the accrual period (September 2006-April 2008)
of this study 72 patients were treated with CRT for
advanced head and neck cancer. Seventeen patients could
not be included, because of patient refusal (N = 4), fol-
low-up known in advance to be abroad (N = 2), adminis-
trative miss (N = 1), cognitive problems (N = 6), or
physical problems (N = 4, i.e. Bechterew's disease, tetra-
plegia, jaw problems), leaving 55 patients (76%) for
inclusion in the study. All 55 patients with a known pri-
mary tumor (advanced stage III and IV squamous cell car-
cinoma) of the oral cavity, oropharynx, hypopharynx,
larynx and nasopharynx, participated in this study. All
patients were eligible for treatment with chemoradiation
with curative intent and were referred to the Netherlands
Cancer Institute for their primary treatment. Data were
collected as baseline measurements for a Randomised
Clinical Trial (RCT) on "Prevention of trismus, swallow-
ing and speech problems in patients treated with chemo-
radiation for advanced head and neck cancer". The
medical ethical review board of the Institute approved the
study protocol, and written informed consent was
obtained from all patients before they entered the study.
The study group consisted of 44 males and 11 females,
with a mean age of 58 years (range 32-79 years). Patients'
characteristics, including tumor sites and stages, are
shown in Table 1. Staging was according to the Interna-
tional Union against Cancer (UICC), 5th edition, 2005.
The majority of the patients (N = 38; 69%) had stage IV
disease; 17 patients (31%) had stage III.
Assessment aspects
The outcomes that were assessed concerned quality of life,
as well as functional aspects such as nutrition, pain, swal-
lowing, mouth opening, and weight changes. The average
time to complete the total comprehensive multidimen-
sional assessment was 90 minutes.
Quality of life, nutrition, pain
Quality of life was assessed by a Dutch study specific ques-
tionnaire, which includes detailed and symptom-specific
questions relevant for this specific cancer group. Further-
more, earlier studies in our institute using this study spe-
cific questionnaire showed its validity [17-19] and did not
reveal any differences when compared to validated stand-
ardized questionnaires such as (QLQ-C30 and QLQ-
H&N35). The advantage of the present questionnaire is
that more specific function-related questions could be
included. This is an important consideration, because
truly function-specific questionnaires such as the MDADI
and the Swalqol were not yet available in Dutch at the
start of this research project [20,21]. The questionnaire
was completed by the patients themselves in the presence
and often with assistance of the first author (LM). Nutri-
tion was evaluated by 1 question of the study specific
questionnaire (see Additional file 1: b4) and using the
Functional Oral Intake Scale (FOIS). The FOIS is a vali-
dated and reliable tool, that consists of a 7-point ordinal
scale, ranging from 1 (nothing by mouth), to 7 (total oral
diet with no restrictions) [22]. Additionally, pain (in the
head and neck region) was assessed using the commonly
used, reliable visual analogue scale (VAS) of 100 mm,BMC Ear, Nose and Throat Disorders 2009, 9:10 http://www.biomedcentral.com/1472-6815/9/10
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where pain between 0-4 mm represents no pain, pain
between 5 mm and 44 mm mild pain, pain between 45-
74 mm moderate pain, and severe pain was scored when
a pain score between 75 to 100 mm was given [23].
Swallowing
Chewing, swallowing function, swallowing frequency,
and the use of drinks during the meal to ease food down
(all patients' perception) were assessed using 9 study spe-
cific structured questions (see Additional file 1: questions
b7-b15).
The clinician-measured swallowing function was evalu-
ated through videofluoroscopy (VFS) using the KAY swal-
lowing workstation (Kay Elemetrics/Pentax, Lincoln Park,
NY, USA). Videofluoroscopy was preferred to, for
instance, FEES [24], because it allows examination of
movement patterns of the bolus and of particular struc-
tures in slow motion and frame by frame. VFS studies pro-
vide information on bolus transit times, motility
problems, and amount, and, most important, etiology of
aspiration [25]. All patients were asked to swallow differ-
ent consistencies of varying amounts twice (1 and 5 cc
thin liquid; 3 cc paste; as well as solid (Omnipaque coated
cake) pretreatment (comparable to protocols used by oth-
ers [8,25]). The ability of the oral cavity and pharynx to
move food efficiently and safely into the esophagus was
assessed using the Penetration and Aspiration Scale (PAS)
and an overall 'presence of residue' score. The PAS is a tool
with an acceptable reliability, and consists of an 8-point
scale, ranging from 1 (material does not enter the airway),
to 8 (material enters the airway, passes below the vocal
folds, and no effort is made to eject) that describes the
depth of aspiration of the swallowed bolus into the airway
[26]. For all consistencies, the first swallow was used for
analysis, both for the PAS and the presence of residue. The
presence of residue was scored as 'no residue', 'residue
above the valleculae' (included 1. the lateral sulcus or
floor of the mouth and/or 2. valleculae (minimal residue
is judged as normal [5,25]); 'residue below the valleculae'
(included 3. posterior wall of the pharynx and/or 4. pyri-
form sinuses) and 'residue above and below the vallecu-
lae'. Each videofluoroscopic study was reviewed in real-
time, slow motion, and frame-by-frame. All swallow stud-
ies were scored by the first author (LM), and several days
later, twenty percent of the videos were scored again to
determine intraobserver reliability of PAS and overall
presence of residue, which were .93 and .93, respectively.
Twenty percent of the tapes were also scored by another
experienced speech language pathologist to determine
inter-observer reliability of PAS and overall presence of
residue, which were .98 and .74, respectively.
Mouth opening
The patients' perceived (subjective) mouth opening was
assessed by the specific question: "How do you experience
your mouth opening?" and by two questions on whether
there are problems caused by a possible limited mouth
opening while eating and speaking (see Additional file 1:
questions b3, b5, b6).
The Maximal Interincisor Opening (MIO) of the mouth
was measured by the clinician using the TheraBite range-
of-motion scale (Atos Medical, Hörby, Sweden). Since the
chemoradiation could cause pain in the mouth, xerosto-
mia, and/or edema, which could prevent patients from
wearing dentures, mouth opening was measured without
dentures (total or partial, depending on the patient). Dijk-
stra et al. (2006) did not find a clear cut-off point for the
Table 1: Patient characteristics (N = 55)
Characteristic Finding (%)
Age in years
Mean 58
Range 32-79
Sex
Male 44 (80)
Female 11 (20)
T category
T1 8 (15)
T2 15 (27)
T3 21 (38)
T4 11 (20)
N category
N0 6 (11)
N1 15 (27)
N2 28 (51)
N3 6 (11)
Stage
III 17 (31)
IV 38 (69)
Tumor sites
Oral cavity 5 (9)
Floor of mouth 2 (4)
Tongue 3 (5)
Oropharynx 24 (44)
Retromolar trigone 1 (2)
Base of tongue 10 (18)
Tonsil 7 (13)
Soft palate 2 (4)
Pharynx posterior wall 3 (5)
Valleculae 1 (2)
Laryngo/hypopharynx 19 (35)
Piriform sinus 17 (31)
Hypopharynx posterior wall 1 (2)
Supraglottic larynx 1 (2)
Nasopharynx 7 (13)BMC Ear, Nose and Throat Disorders 2009, 9:10 http://www.biomedcentral.com/1472-6815/9/10
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subgroups dentate, partially dentate and edentulous, but
a mouth opening of 35 mm or less was regarded as the
cut-off point for trismus of the total group [27]. Therefore,
in this study a cut-off point of 35 mm or less was taken as
the threshold for the total group.
Weight changes
Weight loss and weight gain was measured at the start of
treatment and followed-up. As a prognostic factor, the
average weight of the last six months pretreatment indi-
cated by the patients themselves was compared to the
measured weight at the start of chemoradiation treatment
[10]. Also the clinical prognostic factor Body Mass Index
(BMI) was analyzed, because a recent study by McRackan
et al (2008) suggests that chemoradiation patients with
increased Body Mass Index (BMI; > 25 kg/m2) have
improved swallowing outcomes, longer time to disease
recurrence, and improved survival when compared to
similar patients with lower BMI.
Statistical Analysis
All statistical analyses were performed in SPSS version 15
(SPSS, Inc, Chicago, Illinois). Descriptive statistics were
used to characterize the sample. Categorical variables
were compared using the χ2 test. Pearson's correlation
coefficient was used to investigate relationships among
the different aspects of assessment. The cut-off for a mean-
ingful level of correlation was taken as 0.3. Trial specific
items of the questionnaire were combined into a more
limited set of multiple-item Likert's scales. The reliability
of the scales was assessed with Cronbach's alpha. For all
analyses, a P < .05 was considered statistically significant.
Inter -and intra observer reliability was calculated using
Cohen's kappa.
Results
Quality of life questionnaire, nutrition, pain
The study specific questionnaire provided insight into
pretreatment organ function, as perceived by the patients.
Good to acceptable reliability coefficients (Cronbach's
alpha) were found (Table 2), indicating that a good to rea-
sonable internal consistency of the set of items in the dif-
ferent subscales was achieved.
The overall rating for the social contacts (inviting/visiting/
phoning family/friends) was good for the majority of
patients. Forty four patients (80%) regularly invited fam-
ily or friends to their home and only 11 (20%) did so just
once per month or not at all. The number of patients that
had a good contact with others and did not feel restricted
in their social contacts was 53 (96%) and 41 (75%),
respectively.
Smell and taste was scored 'poor' to 'moderate' in 9 (16%)
and 13 (24%) of the patients, respectively. The correlation
between smell and taste was moderate (R = .566; P < .01),
i.e. patients, who reported a disturbance of taste, also
experienced a significantly poorer sense of smell.
Analyzing nutrition, 44 patients (80%) scored the maxi-
mum value 7 (N = 42; oral diet with no restrictions) or
value 6 (N = 2; oral diet with multiple consistencies with-
out special preparation, but with specific food limita-
tions) on the Functional Oral Intake Scale (FOIS). Three
patients (5%) were tube dependent at the beginning of
the treatment. These 3 patients mentioned that they com-
bined tube-feeding with some attempts or with consistent
oral intake of food or liquid (scale value 2). The remain-
ing 8 patients had an oral diet with restrictions (scale val-
ues 4 and 5).
With regard to pain as measured by VAS there were 24
patients (44%) who reported no pain (0-4 mm) at the
start of the treatment. Twenty three patients (42%)
reported pain less than 44 mm (mild pain). Seven
patients (13%) reported pain between 45 mm and 74 mm
(moderate pain) and one patient experienced severe pain
(2%). Most patients related the pain to the tumor.
Patients with stage III tumors reported more pain than the
patients with stage IV and patients with a tumor in the
oropharynx reported more pain than the other groups,
but these differences were statistically not significant.
Swallowing
Six of the 55 patients (11%) complained about mastica-
tion difficulties. As shown in Table 3, the most frequent
complaints related to the swallowing function concerned
difficulties with the oral phase of solid food (n = 5), and
the pharyngeal phase of solid food (n = 10). The reliability
of a summary scale of the 6 swallowing function items,
measured by Cronbach's alpha, was good (0.763). Fur-
thermore, 23 patients (42%) reported that they had to
swallow more than twice to ingest various food consisten-
Table 2: Reliability coefficient (Cronbach's alpha) of the Likert scales measuring several quality of life issues (see Additional file 1 for 
the corresponding questions)
No. of items Corresponding questions Alpha
Functional Swallowing 6 b. 8,9,10,11,12,13 0.763
Psychosocial Social contacts 3 c. 1,2,3 0.636BMC Ear, Nose and Throat Disorders 2009, 9:10 http://www.biomedcentral.com/1472-6815/9/10
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cies and 27 patients (49%) had to use water to swallow
the food.
The videofluoroscopic studies identified seven patients
(13%) with laryngeal penetration and three (5%) with
overt aspiration before treatment. For the consistency of 1
cc thin liquid approximately one-third of the patients
(38%) showed more than normal residue above the val-
leculae. Presence of residue after 5 cc thin liquids
appeared most frequently (86%) above and below the val-
leculae. For the paste consistency, twenty three patients
(42%) showed more than normal residue above the val-
leculae, and twenty three patients (42%) showed residue
above and below the valleculae after swallowing Omni-
paque coated cake. Overall, only 1 patient (2%) did not
show more than normal residue on any of the consisten-
cies or amounts. This was one of the seven patients with a
nasopharyngeal tumor. No significant correlations
between the Penetration and Aspiration Scale (PAS) or
presence of residue and tumor location or tumor stage
were found.
Mouth opening
Of the total group, 34 patients (62%) were dentate, 8
patients (15%) were partially dentate, and 13 patients
(24%) were edentulous. Patients' perceived trismus,
assessed by 1 question (Additional file 1: question b3)
was reported to be a problem by 7 patients (13% of the
total group). This perceived presence of trismus was
highly correlated with the other 2 questions concerning
the relation between limited mouth opening and difficul-
ties while eating and speaking (R = .684; P < .01) (Addi-
tional file 1: questions b5, b6)
Clinician measured mean Maximal Interincisior Opening
(MIO) of the dentate patients was 45 mm (range 26-66),
for the partially dentate patients it was 50 mm (range 36-
65) and for the edentulous patients it was 60 (range 48 to
69). The mean MIO of the total group was 50 mm (range
26-69). Women had a mean MIO of 45 mm (range 26-67)
and men of 51 mm (30-69). These differences were statis-
tically not significant. Trismus as measured by the clini-
cian was established in 5 patients (9%) of the total group
(two women and three men). The smallest mean MIO was
measured in the group of patients with an oropharyngeal
carcinoma, but there was no significant correlation with
tumor site. Also, no significant correlation existed
between MIO and tumor stage or dentition.
Weight changes
The average body weight 6 months prior to treatment, as
indicated by the patients, was 78.4 kg (range 50-116 kg).
The mean weight measured at the start of the chemoradi-
ation treatment was 77.0 kg (range 50.0-108.0 kg), which
indicates an average weight loss of 1.3%. However, two
categories of patients can be distinguished in this respect,
i.e. patients with or without weight loss. In the first cate-
gory, there were twenty six patients (47%), who suffered
from a weight loss of 7% (mean 5.5 kg, range 0.3-19.4 kg),
whereas in the second category there were two patients
(4%), who had no weight change, and 27 patients (49%),
who gained weight (2.84%, mean 2.2 kg, range 0.2-9.5
kg) in the preceding 6 months. These two groups did not
show significant differences with respect to sex, tumor
location or tumor stage.
The average BMI at the start of treatment was 25.0, with 29
patients (53%) having a BMI of 25 or less. No significant
difference was found with respect to sex. A significant, but
weak correlation was found between tumor location and
BMI (R = .394; P < .01), i.e. a BMI of 25 kg/m2 or lower
occurred significantly more often in patients with a tumor
in the oral cavity or oropharynx, while a BMI higher than
25 occurred significantly more often in patients with a
tumor in the hypopharynx/larynx or nasopharynx. No
other statistically significant differences were found.
Relationship and relevance of the different assessment 
tools
A summary of the results, given separately for each assess-
ment aspect is presented in Table 4. A mark (X) indicates
that an abnormality or problem was found (either by the
clinician or perceived by the patient). All patients had at
least 1 abnormality or problem, and 41 patients (75%)
Table 3: Rating of swallowing (dys)function, in terms of oral and pharyngeal transport, according to the study specific questionnaire 
(Additional file 1: question b8-b13)
N = 55 Not at all A little Quite a bit Very much
Oral transport
Solid food 39 11 4 1
Soft (pureed) food 50 4 1 -
Liquids 53 2 - -
Swallowing
Solid food 27 18 6 4
Soft (pureed) food 46 8 1 -
Liquids 48 6 1 -BMC Ear, Nose and Throat Disorders 2009, 9:10 http://www.biomedcentral.com/1472-6815/9/10
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had 3 or more abnormalities or problems (see Figure 1).
The presence of residue, perceived pain and perceived
swallowing dysfunction were the most common prob-
lems.
Discrepancies exist when comparing the patients' per-
ceived problems with the problems as identified by the
clinician. Three of the 10 patients (30%), who penetrated
or aspirated as judged on the PAS, did not report any swal-
lowing problems. Conversely, of the 12 patients who
reported perceived swallowing problems only 5 patients
showed laryngeal penetration or aspiration (42%). How-
ever, the difference between the PAS and the patients' per-
ceived swallowing problems was not significant.
Trismus measured by the clinician occurred, as already
mentioned, in 5 patients and subjectively, trismus was
perceived by 7 patients (13% of the total group), but in
only 2 of the 7 patients a restricted mouth opening (< 35
mm) was measured by the clinician. The 3 other objective
trismus patients did not report having a limited mouth
opening. Thus, patients with a restricted mouth opening
did not necessarily perceive a limited mouth opening, and
some patients with a 'normal' mouth opening (> 35 mm),
did perceive limited mouth opening. The negative correla-
tion between the clinician measured and the patients' per-
ceived trismus was significant but weak (R = -.359; P <
.01).
A statistically significant correlation was found between
the clinician-rated FOIS and the question 'diet' of the
quality of life questionnaire (R = -.962; P < .01). Patients
who combined tube-feeding with some attempts or with
consistent oral intake of food or liquid (FOIS scale value
2) had also answered the question 'diet' with 'combina-
tion soft diet and tube feeding' (Additional file 1; question
b4; value 5).
A (weak) significant correlation was further found
between weight and FOIS (R = .346; P = .023): patients
who were tube dependent lost more weight than patients
who had no oral restrictions.
Discussion
This study of 55 patients with advanced (stage III and IV)
squamous cell carcinoma of the oral cavity, oropharynx,
hypopharynx, larynx or nasopharynx, shows that in view
of the many abnormalities and problems found and the
lack of positive correlations between the various outcome
instruments, a multidimensional assessment package is
indispensable to evaluate organ function prior to treat-
ment.
Several abnormalities or problems were found by the cli-
nician or experienced by the patient. All patients had at
least 1 problem and 41 patients (75%) had 3 or more
abnormalities or problems. The most common problems
perceived by the patients were swallowing and pain.
Almost two-third of the patients experienced slight swal-
lowing problems, and 20% had to modify their diet
because of these problems. These findings are in accord-
ance with the literature. Many studies reported pretreat-
ment swallowing restrictions assessed by a (quality of life)
questionnaire [7,8,11,28]. It is generally accepted that die-
tary modification should be the initial approach for
patients with swallowing problems [29]. Pain is very
rarely explicitly reported pretreatment and comparable
data are lacking in the literature [4]. This is unfortunate,
because scoring perceived pain (for which a visual ana-
logue scale is an effective and easy method) is an impor-
tant parameter in the clinical follow-up of any cancer
treatment [30].
The most common problems found by the clinician were
the presence of residue visualized during videofluoros-
copy, and weight loss. Presence of residue appeared in
almost all patients for almost all consistencies. These find-
ings are comparable with a study by Pauloski et al. [5].
These authors also found greater amounts of oral and
pharyngeal residue before treatment in head and neck
cancer patients compared with normal control subjects.
Although the inter-observer reliability of residue was rela-
tively low (0.74), and its clinical relevance is unclear, this
aspect of the videofluoroscopy assessment is still relevant
as baseline information with which posttreatment results
should be compared. Nevertheless, the subjective nature
of this scale must be kept in mind. Weight at the onset of
Summary of frequencies of problems detected by the multidi- mensional assessment from Table 4 Figure 1
Summary of frequencies of problems detected by the 
multidimensional assessment from Table 4.BMC Ear, Nose and Throat Disorders 2009, 9:10 http://www.biomedcentral.com/1472-6815/9/10
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Table 4: Overview of all multidimensional assessment categories per patient; a mark (X) indicates that an abnormality or problem was perceived or 
measured in that specific category for that patient.
PATIENTS' PERCIEVED MEASUREMENTS 'OBJECTIVE' CLINICIAN MEASUREMENTS
Qualityof life questionnaire Intake Pain Videofluoroscopy Mouth opening Weight
Pt.n Taste/smell Swallowing Trismus Intake FOIS PAS Residue Trismus Weight loss BMI < 25
1X X X X X
2X X X X X X X
3X X X X X
4X XX X X X X X
5X X X X
6 XX
7X X
8X X X X X X X X X
9X X X X X X X
10 X
11 X X X X X X X X
12 X X X X X
13 X X
14 X X X X
15 X X X X
16 XX X
17 XX
18 XX
19 X X X X X X
20 X X X
21 X
22 X X X X X X X
23 X X X X
24 XX
25 X
26 XX
27 X X X X X X X
28 X X X X X X
29 X X X X X X X X X
30 X X
31 X X X
32 X X X X X X X
33 X XX
34 X X X
35 XX
36 X X X X X
37 X X X X X
38 X
39 X X X X X X
40 XX X
41 X X X X
42 X X X X X
43 X X X X X X X
44 X X X
45 XX X
46 X X X X X
47 X X X X X
48 X X
49 X X X
50 X X X X X X X X
51 XX X
52 X X X X
53 X X X X X
54 X X X X
55 XX XBMC Ear, Nose and Throat Disorders 2009, 9:10 http://www.biomedcentral.com/1472-6815/9/10
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therapy, and especially weight loss in the preceding 6
months and during treatment, are strong predictors for
overall and disease specific survival in head and neck can-
cer patients [31]. In the present study, a weight loss of 7%
was calculated in half of the patients, whereas the other
half showed no weight change or even gained weight.
These figures have to be interpreted with caution since
they are partly based on the patient's memory. Further-
more, patients were instructed to increase their oral intake
directly after the first consultation, which means that they
might have gained some weight by the time the treatment
started. Only a few authors have reported on pretreatment
body weight and even fewer on pretreatment body weight
changes, despite the fact that these changes have prognos-
tic relevance [31].
Body Mass Index (BMI) seems to be an important consid-
eration when predicting the likely outcomes of concurrent
chemotherapy for head and neck cancer patients, as
recently reported by McRackan et al. [32]. These authors
found an average BMI of 24.3, and a better treatment out-
come for the patients with a BMI > 25. The average BMI of
25.0 found in the present study is comparable to the one
reported by McRacken. However, it remains to be seen
whether BMI in the present study population is a strong
predictor of treatment outcome as well, and whether an
actual overweight improves the therapy outcome. For the
moment it does seem worthwhile to include BMI as part
of a thorough assessment.
The multidimensional assessment in this study identified
several functional problems pretreatment. Furthermore,
several problems objectified by the clinician were not per-
ceived as such by patients. For instance, 3 of the 10
patients (30%) who showed laryngeal penetration or
aspirated did not report any swallowing problems, which
is alarming. These patients have an increased risk of aspi-
ration pneumonia and should be monitored very closely
during treatment as well as start with intensive rehabilita-
tion before treatment. If only a questionnaire had been
used, this 'risk' would not have been found and possible
negative consequences could not have been prevented.
Studies that do not combine VMBS examinations with
QOL questionnaires may not identify all relevant func-
tional problems, and therefore, the care these patients
need may be lacking. Another important reason to start
intensive rehabilitation before treatment is the significant
evidence that pretreatment swallowing exercises do
improve post-treatment swallowing function in head and
neck cancer [33].
Limitations of the study
The multidimensional assessment used in this study is not
standard. As far as we know, there is no standard assess-
ment battery that includes all the different aspects that
could be affected in this population. We were therefore
forced to compile an evaluation package, which is
described in this study. There are other assessment tools
available, however, one has to choose as: it is obviously
not realistic to include every available assessment tool.
For our research project we endeavored to find a balance
between thorough, comprehensive evaluation and bur-
den to the patient.
Conclusion
Considerable functional problems and abnormalities
exist pretreatment in patients with advanced head and
neck cancer. The comprehensive multidimensional
assessment used in this study provides good baseline
information for later evaluation of functional outcomes
of the oncologic treatment and/or rehabilitation. Addi-
tionally, this study clearly shows that not only clinical
outcomes measures should be included, but that patients'
views should also be collected in order to gain good
insight in all pre-existing functional and quality of life
problems in these patients.
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